What is the Ideal Blood Pressure Goal for Patients with Stage III or Higher Chronic Kidney Disease?

Hypertension and chronic kidney disease (CKD) are public health problems well known to the national and international medical communities. Blood pressure (BP) control in patients with CKD stage III and IV plays a key factor in reducing cardiovascular risk and renal disease progression. We conducted...

Full description

Saved in:
Bibliographic Details
Published in:Current cardiology reports 2011-12, Vol.13 (6), p.492-501
Main Authors: Khouri, Yazan, Steigerwalt, Susan P., Alsamara, Mershed, McCullough, Peter A.
Format: Article
Language:English
Subjects:
Antihypertensive Agents - therapeutic use
Blood Pressure
Blood Pressure Determination
Cardiology
Cardiovascular Diseases - drug therapy
Cardiovascular Diseases - epidemiology
Cardiovascular Diseases - prevention & control
Controlled Clinical Trials as Topic
Humans
Hypertension (Matthew Sorrentino
Hypertension - complications
Hypertension - drug therapy
Hypertension - epidemiology
Medicine
Medicine & Public Health
Renal Insufficiency, Chronic - complications
Renal Insufficiency, Chronic - epidemiology
Renal Insufficiency, Chronic - physiopathology
Risk Assessment
Section Editor
Severity of Illness Index
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Hypertension and chronic kidney disease (CKD) are public health problems well known to the national and international medical communities. Blood pressure (BP) control in patients with CKD stage III and IV plays a key factor in reducing cardiovascular risk and renal disease progression. We conducted a literature review of recent studies addressing BP targets and cardiorenal outcomes in patients with CKD. Multiple studies demonstrated cardiovascular benefits associated with greater BP reduction. Nevertheless, a U-shaped relationship between BP, cardiovascular events, and renal function was present. In patients with CKD stage III and IV, a BP less than 140/90 mm Hg appeared to be a reasonable target. Moreover, in patients with CKD and proteinuria of more than 1 g/day, a target systolic BP of 120 to 130 mm Hg and diastolic BP of 70 to 80 mm Hg yielded the greatest benefit while avoiding most of the adverse cardiovascular outcomes associated with lower levels of BP.
ISSN:1523-3782
1534-3170
DOI:10.1007/s11886-011-0215-0